RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.
NoxSudor introduces a drug to combat night sweats and hot flushes.
Investment closes only once the total pledged amount passes the minimum of £350,000
A pledge is not a commitment. You will be asked to confirm in the next section.
This company has not shared it's twitter feed.
NoxSudor Therapeutics Limited has an exclusive licencing agreement for a food supplement product, Ospera, which alleviates the menopausal symptoms of hot flashes and night sweats. Hot flashes and night sweats are a global underserved medical condition. They affect about 80% of menopausal women with symptoms usually lasting for 5-10 years. Current solutions are either unattractive or ineffective. The company has completed R&D and independent CRO clinical safety trial and is ready to go to the market. Noxsudor is raising money for its UK launch and intends to become the product of choice for menopausal women in the UK, then worldwide.
Investment Focus: Equity and Debt
About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.
Contact Name: Oliver Woolley
Registered InvestorsOver 1000
Investment through platformOver £100m